BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25759025)

  • 1. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.
    Geng H; Hurtz C; Lenz KB; Chen Z; Baumjohann D; Thompson S; Goloviznina NA; Chen WY; Huan J; LaTocha D; Ballabio E; Xiao G; Lee JW; Deucher A; Qi Z; Park E; Huang C; Nahar R; Kweon SM; Shojaee S; Chan LN; Yu J; Kornblau SM; Bijl JJ; Ye BH; Ansel KM; Paietta E; Melnick A; Hunger SP; Kurre P; Tyner JW; Loh ML; Roeder RG; Druker BJ; Burger JA; Milne TA; Chang BH; Müschen M
    Cancer Cell; 2015 Mar; 27(3):409-25. PubMed ID: 25759025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
    Chen Z; Shojaee S; Buchner M; Geng H; Lee JW; Klemm L; Titz B; Graeber TG; Park E; Tan YX; Satterthwaite A; Paietta E; Hunger SP; Willman CL; Melnick A; Loh ML; Jung JU; Coligan JE; Bolland S; Mak TW; Limnander A; Jumaa H; Reth M; Weiss A; Lowell CA; Müschen M
    Nature; 2015 May; 521(7552):357-61. PubMed ID: 25799995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
    Juszczynski P; Chen L; O'Donnell E; Polo JM; Ranuncolo SM; Dalla-Favera R; Melnick A; Shipp MA
    Blood; 2009 Dec; 114(26):5315-21. PubMed ID: 19855081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia.
    Erasmus MF; Matlawska-Wasowska K; Kinjyo I; Mahajan A; Winter SS; Xu L; Horowitz M; Lidke DS; Wilson BS
    Sci Signal; 2016 Nov; 9(456):ra116. PubMed ID: 27899526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
    Müschen M
    Blood; 2015 Jun; 125(24):3688-93. PubMed ID: 25878119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pre-BCR to the rescue: therapeutic targeting of pre-B cell ALL.
    Trimarchi T; Aifantis I
    Cancer Cell; 2015 Mar; 27(3):321-3. PubMed ID: 25759017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.
    Feldhahn N; Henke N; Melchior K; Duy C; Soh BN; Klein F; von Levetzow G; Giebel B; Li A; Hofmann WK; Jumaa H; Müschen M
    J Exp Med; 2007 May; 204(5):1157-66. PubMed ID: 17485517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
    Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
    Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAG-mediated DNA double-strand breaks activate a cell type-specific checkpoint to inhibit pre-B cell receptor signals.
    Bednarski JJ; Pandey R; Schulte E; White LS; Chen BR; Sandoval GJ; Kohyama M; Haldar M; Nickless A; Trott A; Cheng G; Murphy KM; Bassing CH; Payton JE; Sleckman BP
    J Exp Med; 2016 Feb; 213(2):209-23. PubMed ID: 26834154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.
    Fujimoto M; Poe JC; Jansen PJ; Sato S; Tedder TF
    J Immunol; 1999 Jun; 162(12):7088-94. PubMed ID: 10358152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.
    Nahar R; Ramezani-Rad P; Mossner M; Duy C; Cerchietti L; Geng H; Dovat S; Jumaa H; Ye BH; Melnick A; Müschen M
    Blood; 2011 Oct; 118(15):4174-8. PubMed ID: 21856866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway.
    Hiratsuka T; Takei Y; Ohmori R; Imai Y; Ozeki M; Tamaki K; Haga H; Nakamura T; Tsuruyama T
    Oncogene; 2016 Jun; 35(25):3227-38. PubMed ID: 26522721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.
    Duy C; Hurtz C; Shojaee S; Cerchietti L; Geng H; Swaminathan S; Klemm L; Kweon SM; Nahar R; Braig M; Park E; Kim YM; Hofmann WK; Herzog S; Jumaa H; Koeffler HP; Yu JJ; Heisterkamp N; Graeber TG; Wu H; Ye BH; Melnick A; Müschen M
    Nature; 2011 May; 473(7347):384-8. PubMed ID: 21593872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
    Craxton A; Jiang A; Kurosaki T; Clark EA
    J Biol Chem; 1999 Oct; 274(43):30644-50. PubMed ID: 10521450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
    Köhrer S; Havranek O; Seyfried F; Hurtz C; Coffey GP; Kim E; Ten Hacken E; Jäger U; Vanura K; O'Brien S; Thomas DA; Kantarjian H; Ghosh D; Wang Z; Zhang M; Ma W; Jumaa H; Debatin KM; Müschen M; Meyer LH; Davis RE; Burger JA
    Leukemia; 2016 Jun; 30(6):1246-54. PubMed ID: 26847027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monovalent and multivalent ligation of the B cell receptor exhibit differential dependence upon Syk and Src family kinases.
    Mukherjee S; Zhu J; Zikherman J; Parameswaran R; Kadlecek TA; Wang Q; Au-Yeung B; Ploegh H; Kuriyan J; Das J; Weiss A
    Sci Signal; 2013 Jan; 6(256):ra1. PubMed ID: 23281368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.
    Feldhahn N; Klein F; Mooster JL; Hadweh P; Sprangers M; Wartenberg M; Bekhite MM; Hofmann WK; Herzog S; Jumaa H; Rowley JD; Müschen M
    J Exp Med; 2005 Jun; 201(11):1837-52. PubMed ID: 15939795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
    Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Processing of CD74 by the Intramembrane Protease SPPL2a Is Critical for B Cell Receptor Signaling in Transitional B Cells.
    Hüttl S; Kläsener K; Schweizer M; Schneppenheim J; Oberg HH; Kabelitz D; Reth M; Saftig P; Schröder B
    J Immunol; 2015 Aug; 195(4):1548-63. PubMed ID: 26157172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.